![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
A Phase 2a, randomized, active-comparator-controlled, open-label study
to evaluate the efficacy and safety of efinopegdutide in individuals with
nonalcoholic fatty liver disease
|
|
|
EASL 2023 June 23 Vienna
Manuel Romero-Gómez1, Eric Lawitz2, R. Ravi Shankar3, Eirum Chaudhri3, Jie Liu3, Raymond Lam3, Keith D. Kaufman3, Samuel Engel3
1University of Seville/ Virgen del Rocio University Hospital, Institute of Biomedicine of Seville (HUVR/CSIC/US)/ Digestive Diseases Unit and CIBERehd, Sevilla, Spain; 2Texas Liver Institute, University of Texas Health San Antonio, San Antonio, TX, USA; 3MRL, Merck & Co., Inc., Rahway, NJ, USA
![0628231](../images/062823/062723-5/0628231.gif)
![0628232](../images/062823/062723-5/0628232.gif)
![0628233](../images/062823/062723-5/0628233.gif)
![0628234](../images/062823/062723-5/0628234.gif)
![0628235](../images/062823/062723-5/0628235.gif)
![0628236](../images/062823/062723-5/0628236.gif)
![0628237](../images/062823/062723-5/0628237.gif)
![0628238](../images/062823/062723-5/0628238.gif)
![0628239](../images/062823/062723-5/0628239.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|